Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
Management
Medical & Scientific Advisory Board
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
NeuCA15-3 Test
NeuCA125 Test
EXO-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
24-Feb-2021
Commencement of Legal Proceedings Against BARD1
23-Feb-2021
Appendix 2A
18-Feb-2021
Ceasing to be a substantial holder
17-Feb-2021
Becoming a substantial holder
15-Feb-2021
Excellent SubB2M Breast Cancer Test Data
11-Feb-2021
Outstanding SubB2M Ovarian Cancer Test Data
9-Feb-2021
Change of Auditor
29-Jan-2021
Appendix 4C & Quarterly Activities Report
28-Jan-2021
U.S. Patent Granted for NET Technology for Exosome Capture
15-Jan-2021
Final Director's Interest Notice - Dr Irminger-Finger
Previous
1
2
3
4
5
6
7
8
9
Next
